The role of allogeneic stem cell transplantation in Hodgkin's lymphoma

Current Treatment Options in Oncology

Volumn 15, Issue 2, 2014, Pages 238-247

  Sureda, Anna ^a   Domenech, E ^a   Schmitz, N ^b   Dreger, P ^c  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allogeneic stem cell transplantation; Graft versus Hodgkin's lymphoma effect; Hodgkin's lymphoma; Reduced intensity conditioning regimen; Refractory disease

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE; CAC10-VCMMAE; HLA ANTIGEN; OLIGOPEPTIDE; VEDOTIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DONOR SELECTION; DRUG APPROVAL; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VERSUS LYMPHOMA EFFECT; HLA MATCHING; HODGKIN DISEASE; HUMAN; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE; ADULT; AGE; ALLOTRANSPLANTATION; CHEMISTRY; DONOR; IMMUNOSUPPRESSIVE TREATMENT; MICROTUBULE; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; REMISSION; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; GRAFT VS TUMOR EFFECT; HLA ANTIGENS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MICROTUBULES; MIDDLE AGED; OLIGOPEPTIDES; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84902362699     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0287-3     Document Type: Article

References (26)

1. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630-7. (Pubitemid 34111368)
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-95. (Pubitemid 36682817)
3. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219-34.
4. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051-4. (Pubitemid 23114397)
5. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease. Lancet. 2002;359:2065-71. (Pubitemid 34680969)
6. Martínez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol. 2013;24:2430-4.
7. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-73. (Pubitemid 9198740)
8. Weiden PL, Sullivan KM, Flournoy N, et al. Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-33. (Pubitemid 11065939)
9. Gajewski JL, Philips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996;14:572-8. (Pubitemid 26051023)
10. Milpied N, Fielding AK, Pearce RM, Erns P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol. 1996;14:1291-6. (Pubitemid 26105538)
11. •• Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455-62. A total of 168 patients with Hodgkin's lymphoma undergoing a first allogeneic stem cell transplantation [reduced intensity conditioning (RIC), n=89; myeloablative conditioning, n=79] between January 1997 and December 2001 were compared. Nonrelapse mortality was significantly decreased in the RIC group, overall survival was better in the RIC group, and there was a trend for better progression-free survival in the RIC group. The development of chronic graft-versus- host disease significantly decreased the incidence of relapse, which translated into a trend for a better progres-sion- free survival.
12. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230-8.
13. Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35:943-51. (Pubitemid 40711829)
14. Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12:172-83. (Pubitemid 43138012)
15. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365:1934-41. (Pubitemid 40797503)
16. •• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310-7. In this phase II study, 92 patients with relapsed Hodgkin's lymphoma were treated with salvage chemotherapy followed by reduced-intensity allogeneic transplantation. Seventy-eight patients proceeded to allograft. Fludarabine (150 mg/m(2) iv) and melphalan (140 mg/m(2) iv) were used as the conditioning regimen. The nonrelapse mortality rate was 8% at 100 days and 15% at 1 year. Relapse was the major cause of failure. The progression-free survival rate was 47% at 1 year and 18% at 4 years from trial entry. The overall survival rate was 71% at 1 year and 43% at 4 years. Chronic graft-versus-host disease was associated with a lower incidence of relapse. Patients allografted in complete remission had a significantly better outcome.
17. •• Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol. 2011;29:971-8. Forty-nine patients with multiply relapsed Hodgkin's lymphoma were allografted using in vivo T-cell depletion as graft-versus-host disease prophylaxis. Eight of 49 (16%) had grade II-IV acute GVHD and 7 (14%) had chronic GVHD before donor-lymphocyte infusion. Sixteen (33%) patients received donor-lymphocyte infusion from 3 months after transplantation for residual disease or progression. Nonrelapse-related mortality was 16.3% at 730 days. Projected 4-year overall and progression-free survival were 55.7% and 39%, respectively.
18. •• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30:2183-9. The efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin's lymphoma after autologous stem-cell transplantation. A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The overall response rate was 75% with complete remission in 34% of patients. The median progression-free survival time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea.
19. • Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119:6379-81. Eighteen patients with refractory Hodgkin's lymphoma, candidates for allogeneic stem cell transplantation and having received brentuximab vedotin before the allogeneic procedure, were analyzed. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0%. The incidence of acute graft-versus-host disease was 27.8% and chronic graft-versus-host disease was 56.3%. Brentuximab vedotin before reduced-intensity allogeneic stem cell transplantation did not adversely affect engraftment, GVHD, or survival and provided sufficient disease control to enable the transplantation procedure.
20. Chen R, Palmer J, Tsai NC, et al. Brentuximab vedotin improves HCT-CI, CR status, and peritransplant toxicity in patients with relapsed/refractory Hodgkin lymphoma heading to RIC Allo-HCT. Blood. 2013;122:3374.
21. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant. 2008;41:765-70. (Pubitemid 351696339)
22. Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671-7.
23. Gopal AK, Chen R, Smith SE, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing Phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2013;122:4382.
24. Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009;114:2060-7.
25. • Thomson K, Kayani I, Ardeshna KM, et al. A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin lymphoma. Leukemia. 2013;27:1419-22. A response-adjusted transplantation algorithm using allogeneic stem cell transplantation with a BEAM-Campath conditioning protocol for those patients deemed to be at high risk of failure of autologous stem cell transplantation because of a metabolically active disease after first-line salvage chemotherapy is analyzed.
26. Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transpant. 2014;49:190-4.